High-concentration monoclonal antibody (mAb) formulations present major bioprocessing challenges, including increased viscosity, protein aggregation, and difficulties in process control. In this webinar, we demonstrate how process analytical technology (PAT) enables automated and optimized ultrafiltration/diafiltration (UF/DF) for high-concentration biologics, presenting a case study of the tangential flow filtration (TFF) KrosFlo® FS-15 RPM™ system with FlowVPX® in-line analytics.
Using a concentration–diafiltration–concentration (C/D/C) strategy, this method of integrating process analytics to your workflow delivers real-time monitoring, precise control, and improved accuracy—which mitigates risks associated with manual operation. Results presented show reliable performance at concentrations exceeding 200 g/L, with excellent comparability between in-line and at-line protein concentration measurements.
Key Learning Objectives:
Attendees will learn how automated tangential flow filtration (TFF) with RPM technology:
- Maintains target protein concentrations and diafiltration volumes (DVs)
- Reduces human error and manual calculation complexity
- Enhances reproducibility and scalability in downstream processing
- Accelerates development timelines for high-concentration biologics
Who Should Attend:
This webinar is ideal for scientists, process engineers, and biomanufacturing professionals working with monoclonal antibodies, high-concentration biologics, and downstream UF/DF processes. Join us to explore how automated, scalable TFF solutions can improve process control, reduce risk, and streamline biopharmaceutical manufacturing.